Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
2,221 to 2,240 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Emerging Roles of FTO in Neuropsychiatric Disorders. | Biomed Res Int | 2022 | 35528183 | PubTator, text mining | PubMed |
| LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. | J Hematol Oncol | 2022 | 35526050 | PubTator, text mining | PubMed |
| FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cells. | Clin Exp Metastasis | 2022 | 35524932 | PubTator, text mining | PubMed |
| The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. | Clin Transl Med | 2022 | 35522946 | PubTator, text mining | PubMed |
| Molecular Characteristics of m6A Regulators and Tumor Microenvironment Infiltration in Soft Tissue Sarcoma: A Gene-Based Study. | Front Bioeng Biotechnol | 2022 | 35519620 | PubTator, text mining | PubMed |
| The Potential Role of m6A RNA Methylation in the Aging Process and Aging-Associated Diseases. | Front Genet | 2022 | 35518355 | PubTator, text mining | PubMed |
| Identification and Characterization of a Glucometabolic Prognostic Gene Signature in Neuroblastoma based on N6-methyladenosine Eraser ALKBH5. | J Cancer | 2022 | 35517412 | PubTator, text mining | PubMed |
| Gene model-related m6A expression levels predict the risk of preeclampsia. | BMC Med Genomics | 2022 | 35513840 | PubTator, text mining | PubMed |
| The Mettl3 epitranscriptomic writer amplifies p53 stress responses. | Mol Cell | 2022 | 35512709 | PubTator, text mining | PubMed |
| Epitranscriptomics in fibroblasts and fibrosis. | Am J Physiol Cell Physiol | 2022 | 35508185 | PubTator, text mining | PubMed |
| Biological networks in gestational diabetes mellitus: insights into the mechanism of crosstalk between long non-coding RNA and N6-methyladenine modification. | BMC Pregnancy Childbirth | 2022 | 35505296 | PubTator, text mining | PubMed |
| METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF/RAD51 axis. | Elife | 2022 | 35502895 | PubTator, text mining | PubMed |
| N6-methyladenosine (m6A) reader IGF2BP2 promotes gastric cancer progression via targeting SIRT1. | Bioengineered | 2022 | 35502827 | PubTator, text mining | PubMed |
| Insufficient ablation induces E3-ligase Nedd4 to promote hepatocellular carcinoma progression by tuning TGF-β signaling. | Oncogene | 2022 | 35501461 | PubTator, text mining | PubMed |
| Roles and mechanisms of the m6A reader YTHDC1 in biological processes and diseases. | Cell Death Discov | 2022 | 35501308 | PubTator, text mining | PubMed |
| m6A RNA Methylation Regulators Contribute to Predict and as a Therapy Target of Pulmonary Fibrosis. | Evid Based Complement Alternat Med | 2022 | 35497924 | PubTator, text mining | PubMed |
| m6A-mediated modulation coupled with transcriptional regulation shapes long noncoding RNA repertoire of the cGAS-STING signaling. | Comput Struct Biotechnol J | 2022 | 35495108 | PubTator, text mining | PubMed |
| YY1-Targeted RBM15B Promotes Hepatocellular Carcinoma Cell Proliferation and Sorafenib Resistance by Promoting TRAM2 Expression in an m6A-Dependent Manner. | Front Oncol | 2022 | 35494016 | PubTator, text mining | PubMed |
| Impacts of MicroRNAs Induced by the Gut Microbiome on Regulating the Development of Colorectal Cancer. | Front Cell Infect Microbiol | 2022 | 35493741 | PubTator, text mining | PubMed |
| Novel prognostic biomarkers, METTL14 and YTHDF2, associated with RNA methylation in Ewing's sarcoma. | Sci Rep | 2022 | 35487915 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=112